First Generation Capital Inc. Acquires Shares of Trimel Pharmaceuticals Corpoariton
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 04/24/13 -- First Generation Capital Inc. ("FGCI"), announced today that it acquired 18,750,000 common shares of Trimel Pharmaceuticals Corporation (the "Issuer"). The purchase was made pursuant to the Issuer's final prospectus, dated April 18, 2013, at $0.80 per common share. FGCI is a private investment holding company owned by Mr. Ian Ihnatowycz (collectively with FGCI, the "Offerors").
Following the purchase, the Offerors hold a total of 21,752,500 common shares of the Issuer, corresponding to a securityholding percentage, calculated in accordance with National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues of approximately 15.45%.
The securities of the Issuer were acquired for investment purposes. Depending upon the circumstances, the Offerors may, from time to time, acquire additional securities or related financial instruments of the Issuer or dispose of all or a portion of the securities or related financial instruments of the Issuer previously acquired.
The issuance of this news release is not an admission that any entity named herein owns or controls any described securities or is a joint actor with another named entity.
Additional information is provided in the early warning report filed on .
Contacts:
For further information or a copy of
the early warning report please contact:
First Generation Capital Inc.
40 King Street West, Suite 3515, Toronto, ON M5H 3Y2
Attention: Ian Ihnatowycz, President and CEO
(416) 304-9910
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.04.2013 - 13:00 Uhr
Sprache: Deutsch
News-ID 1219961
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Venture Capital
Anmerkungen:
Diese Pressemitteilung wurde bisher 122 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"First Generation Capital Inc. Acquires Shares of Trimel Pharmaceuticals Corpoariton
"
steht unter der journalistisch-redaktionellen Verantwortung von
First Generation Capital Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
